- Home >
- Clinicals Trials >
- GLORIOSA
Cancers gynécologiques
GLORIOSA
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA).
- Open at Paris since : 13/09/2024
- Target : Adult
- Phase : Phase III
Trial description
To compare progression-free survival (PFS), as assessed by the investigator per the;Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), after;platinum-based chemotherapy (doublet) plus bevacizumab and randomized to;maintenance mirvetuximab soravtansine (MIRV) plus bevacizumab (Arm 1) versus;bevacizumab alone (Arm 2);- PFS will also be assessed, as a sensitivity analysis, by a blinded independent;central review (BICR) in the same patient population.
Url of the trial